Retatrutide Protocol (24 weeks)
Investigational triple-agonist (GLP-1/GIP/glucagon) Phase 2 trial titration: 2 → 4 → 8 → 12 mg weekly, escalating every 4 weeks to the 12mg maintenance dose.
Concentration over time
ng/mLModel details: Retatrutide · estimated
How to read this estimate
Estimated from study endpoints; the curve between measurements is reconstructed. Compare amounts and timing in mg.
A concentration estimate reconstructed from the stated source dose and timing.
Assumptions, calculation and sources
LY3437943 trial injection, prepared from 5 mg vials reconstituted with sterile water or saline.. subcutaneous. Healthy adults, Singapore single-ascending-dose study; 1 mg cohort n=6..
retatrutide: estimated concentration in plasma (ng/mL).
Coskun 2022 Table 1, 1 mg cohort: geometric mean terminal half-life134h; median Tmax48h.
- Calibration dose
- 1 mg
- Reported calibration peak
- 110 ng/mL
- Peak timing used
- 48 hours
- Terminal half-life used
- 134 hours
- Reconstructed absorption rate
- 0.05406351 /hour
- Observed extravascular concentrations already contain bioavailability; do not multiply by legacy F or add an independently assumed F.
- Dose scaling and repeated-dose superposition use fixed parameters; the example dose does not calibrate the curve.
- Linear dose scaling/repeated-dose superposition is an approximation, although the trial describes nearly proportional PK.
- Other dose cohorts differ; the estimate is not a pooled population fit and does not recreate every dose-cohort mean.
- No molecular-weight conversion is required; do not preserve old nmol/L label over ng/mL values.
- Coskun et al. 2022, Cell Metabolism, Table 1
1 mg single SC: Cmax110ng/mL; Tmax48h; half-life134h; AUCinf28300ng*h/mL. Publisher full text including table was inspected through search index; direct publisher fetch returned403.
- NCT03841630
Identifies healthy-adult first-in-human single-dose trial.
Estimate retatrutide-source-estimate-2026-10 · version 1
| Date | Retatrutide · Estimated levels (ng/mL) |
|---|---|
| W1 | 0 ng/mL |
| W3 | 185.58 ng/mL |
| W5 | 218.223 ng/mL |
| W7 | 409.544 ng/mL |
| W9 | 443.197 ng/mL |
| W11 | 820.275 ng/mL |
| W13 | 886.602 ng/mL |
| W15 | 1269.43 ng/mL |
| W17 | 1336.76 ng/mL |
| W19 | 1348.61 ng/mL |
| W21 | 1350.69 ng/mL |
| W23 | 1351.06 ng/mL |
| W25 | 1351.12 ng/mL |
The chart uses a bounded time grid. Long horizons can miss brief peaks between samples; shorten the horizon to inspect more detail. Chart peaks are sampled values.
Protocol summary
Retatrutide Protocol (24 weeks) · 24 weeks starting Oct 15, 26
- Retatrutide — 2.00 mg Every 7 days, weeks 0–3
- Retatrutide — 4.00 mg Every 7 days, weeks 4–7
- Retatrutide — 8.00 mg Every 7 days, weeks 8–11
- Retatrutide — 12.0 mg Every 7 days, weeks 12–24
Protocol overview
- Category
- weightloss
- Duration
- 24 weeks
- Compounds
- 4
- Tags
- glp-1, gip, glucagon, investigational, retatrutide
Compounds in this protocol
- Retatrutide 2mg — 2 mg, every-7-days (weeks 0-3)
- Retatrutide 4mg — 4 mg, every-7-days (weeks 4-7)
- Retatrutide 8mg — 8 mg, every-7-days (weeks 8-11)
- Retatrutide 12mg — 12 mg, every-7-days (weeks 12-24)
How to read this protocol
The chart shows available model curves over the 24-week example. Rows whose model is unavailable are retained for context but produce no curve. Read each model’s details for what its line represents; a plotted level does not predict treatment effects or establish a suitable dose.
The peak/trough explorer examines one complete model interval. The single-dose decline explorer is a separate one-dose scenario; it does not calculate this protocol's washout or a safe treatment-change date. The compound comparison shows available model outputs, not equivalent clinical effects.
Educational only. Not medical advice. These examples do not predict individual blood levels.